Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., AUG. 27, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN ONE UPCOMING INVESTOR CONFERENCE IN SEPTEMBER.

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCE

SOUTH SAN FRANCISCO, CALIF., AUG. 13, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC.(NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY PROVIDED CORPORATE UPDATES AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

ALLOGENE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

SOUTH SAN FRANCISCO, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC.(NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCEDTHAT IT WILL REPORT THE SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON AUGUST 13, 2025, AFTER THE CLOSE OF THE MARKET. THE ANNOUNCEMENT WILL BE FOLLOWED BY A LIVE AUDIO WEBCAST AND CONFERENCE CALL AT 2:00 P.M. PT/5:00 P.M. ET.

ALLOGENE THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

SOUTH SAN FRANCISCO, CALIF., AUG. 01, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC.(NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT IT HAS SELECTED STANDARD FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) AS THE LYMPHODEPLETION REGIMEN TO BE USED IN ITS ALPHA3 STUDY EVALUATING CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST-LINE CONSOLIDATION FOR LARGE B-CELL LYMPHOMA (LBCL). THIS LYMPHODEPLETION REGIMEN SELECTION WAS MADE IN CONJUNCTION WITH THE ALPHA3 DATA AND SAFETY MONITORING BOARD (DSMB) AND STEERING COMMITTEE AND FOLLOWING CONSULTATION WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA).

ALLOGENE THERAPEUTICS MOVES FORWARD WITH STANDARD FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) LYMPHODEPLETION REGIMEN IN THE ALPHA3 TRIAL FOR CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST-LINE CONSOLIDATION FOR LARGE B-CELL LYMPHOMA

SOUTH SAN FRANCISCO, CALIF., JUNE 01, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, PRESENTED UPDATED DATA FROM THE PHASE 1 TRAVERSE STUDY OF ALLO-316 IN RENAL CELL CARCINOMA (RCC) DURING AN ORAL PRESENTATION AT THE 2025 ASCO ANNUAL MEETING. THE PHASE 1 TRAVERSE TRIAL ENROLLED PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL RCC. LEVERAGING THE PROPRIETARY DAGGER TECHNOLOGY TO ENABLE ROBUST CAR T CELL EXPANSION, IT STANDS AS THE FIRST AND ONLY ALLOGENEIC CAR T PRODUCT TO SHOW PROMISE IN TREATING SOLID TUMORS. THE PRESENTATION FOCUSED ON THE PHASE 1B EXPANSION COHORT FROM THE PHASE 1 TRAVERSE STUDY IN WHICH PATIENTS WERE TREATED WITH A STANDARD REGIMEN OF CYCLOPHOSPHAMIDE AND FLUDARABINE FOLLOWED BY A SINGLE DOSE OF 80 MILLION ALLOCAR T CELLS.

ALLOGENE THERAPEUTICS PROVIDES UPDATED PHASE 1 DATA HIGHLIGHTING DURABLE RESPONSES WITH ALLO-316 IN HEAVILY PRETREATED ADVANCED RENAL CELL CARCINOMA AT ASCO

SOUTH SAN FRANCISCO, CALIF., MAY 23, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN FOUR UPCOMING INVESTOR CONFERENCES IN MAY AND JUNE.

ALLOGENE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., MAY 22, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE,TODAY ANNOUNCED THE PUBLICATION OF TWO ABSTRACTS ON THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) WEBSITE IN ADVANCE OF THE 2025 ASCO ANNUAL MEETING, TAKING PLACE MAY 30-JUNE 3 IN CHICAGO, ILLINOIS.

ALLOGENE THERAPEUTICS ANNOUNCES ASCO 2025 ABSTRACT PUBLICATION FEATURING ORAL PRESENTATION OF ALLO-316 IN KIDNEY CANCER AND ALPHA3 TIP POSTER FOR CEMA-CEL

PIVOTAL PHASE 2 ALPHA3 TRIAL WITH CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST LINE (1L) CONSOLIDATION IN LARGE B-CELL LYMPHOMA (LBCL) NEARLY 50 SITES ACTIVATED ACROSS U.S. WITH STRONG ENTHUSIASM FROM INVESTIGATORS LYMPHODEPLETION SELECTION AND FUTILITY ANALYSIS SHIFTED TO 1H 2026 IN PART DUE TO SITE-RELATED FACTORS THAT IMPACTED EXPECTED PACE OF SCREENING IMMEDIATELY FOLLOWING SITE ACTIVATION OVER 250 PATIENTS CONSENTED FOR MRD SCREENING TO DATE, WITH NEARLY HALF IN THE LAST THREE MONTHS AND AWAITING COMPLETION OF 1L TREATMENT AS EARLIEST ACTIVATED SITES BUILD MOMENTUM INTERNATIONAL EXPANSION OF ALPHA3 TRIAL TO BEGIN WITH SITE ACTIVATIONS IN CANADA IN Q2 2025 PHASE 1 RESOLUTION TRIAL WITH ALLO-329 IN AUTOIMMUNE DISEASE (AID) RESOLUTION BASKET TRIAL IN RHEUMATOLOGY ON TRACK FOR MID-2025 START PROOF-OF-CONCEPT DATAMOVED TO 1H 2026 TO ENABLE INCLUSION OF BOTH BIOMARKER AND CLINICAL DATA PHASE 1 TRAVERSE TRIAL WITH ALLO-316 IN RENAL CELL CARCINOMA (RCC) UPDATED PHASE 1 TRIAL RESULTS WILL BE FEATURED IN AN ORAL PRESENTATION AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING PRESENTATION TO HIGHLIGHT MEANINGFUL CLINICAL RESPONSES FROM THE PHASE 1B EXPANSION COHORT AND KEY TRANSLATIONAL FINDINGS, INCLUDING ABILITY FOR CD70 DAGGER TECHNOLOGY TO DRIVE ROBUST CAR T CELL EXPANSION AND PERSISTENCE ENDED Q1 2025 WITH$335.5 MILLIONIN CASH, CASH EQUIVALENTS AND INVESTMENTS COST REALIGNMENT AND STRATEGIC PRIORITIZATION WILL EXTEND CASH RUNWAY INTO 2H 2027 SPEND FOCUSED ON ADVANCING THE CEMA-CEL/ALPHA3 AND ALLO-329/RESOLUTION CLINICAL TRIALS TO KEY INFLECTION POINTS TARGETED REDUCTIONS IN MANUFACTURING OPERATIONS PROVIDE KEY SAVINGS WHILE PRESERVING CORE CAPABILITIES CONFERENCE CALL AND WEBCAST SCHEDULED FORTODAY AT 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, CALIF., MAY 13, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC.(NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER A

ALLOGENE THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSAND BUSINESS UPDATE

CONFERENCE CALL AND WEBCAST SCHEDULED FOR MAY 13, 2025 AT 2:00 P.M. PT/5:00 P.M.

ALLOGENE THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE

SOUTH SAN FRANCISCO, CALIF., APRIL 23, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE,TODAY ANNOUNCED THAT IT WILL PRESENT UPDATED DATA FROM THE COMPLETED PHASE 1 TRAVERSE TRIAL OF ALLO-316 IN AN ORAL PRESENTATION AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TAKING PLACE MAY 29-JUNE 2 IN CHICAGO, ILLINOIS. THE TRIAL EVALUATED ALLO-316 IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA (RCC) WHO HAD PROGRESSED FOLLOWING IMMUNE CHECKPOINT INHIBITOR AND VEGF-TARGETED THERAPIES. IN ADDITION, A TRIAL-IN-PROGRESS POSTER IS ALSO BEING PRESENTED TO HIGHLIGHT THE ONGOING PIVOTAL PHASE 2 ALPHA3 TRIAL, WHICH IS EVALUATING CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) AS PART OF FIRST-LINE (1L) TREATMENT FOR PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL).

ALLOGENE THERAPEUTICS TO PRESENT UPDATED ALLO-316 CLINICAL RESULTS IN KIDNEY CANCER IN ORAL PRESENTATION AND ALPHA3 TRIAL-IN-PROGRESS POSTER FOR CEMA-CEL AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

SOUTH SAN FRANCISCO, CALIF., APRIL 07, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC. (NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT ALLO-329, AN INVESTIGATIONAL DUAL-TARGETED CD19/CD70 ALLOGENEIC CAR T, HAS RECEIVED THREE FAST TRACK DESIGNATIONS (FTD) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ADULT PATIENTS WITH:

ALLOGENE GRANTED THREE U.S. FDA FAST TRACK DESIGNATIONS (FTD) FOR ALLO-329, A NEXT-GENERATION DUAL-TARGETED CD19/CD70 ALLOGENEIC CAR T, FOR THE TREATMENT OF LUPUS, MYOSITIS AND SCLERODERMA

Allogene Therapeutics, Inc.

ALLO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Allogene Therapeutics, Inc.

ALLO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ALLO